Not applicableNot Yet RecruitingNCT07387861
What this trial is testing
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study
Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70